Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PURR-16
- Development stage
- Preclinical
- Lead developer
- The Cat Health Company
01
Overview
PURR-16 is an investigational veterinary therapeutic candidate being developed by The Cat Health Company, a biotechnology firm focused on feline longevity and age-related diseases. The drug is part of the company's 'PURR' pipeline, which is designed to address common geriatric conditions in senior cats to extend their healthy lifespan. PURR-16 is specifically targeted toward mitigating the progression of sarcopenia (muscle wasting), chronic kidney disease (CKD), and neurodegeneration. While the company follows a structured development path including IND-enabling studies and clinical trials, specific details regarding the molecular target, modality, and precise mechanism of action for PURR-16 have not been publicly disclosed.
Beyond the preview
Go deeper on PURR-16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PURR-16.